Insider filing · SNDX
Michael A Metzger
Chief Executive Officer
profile →
Syndax Pharmaceuticals, Inc.
SNDX · Healthcare · 10 filings in 24 months
ticker →
Michael A Metzger sold $2.6M of Syndax Pharmaceuticals (SNDX)
Executed Sep 8 2025, disclosed Sep 8 2025, the same day.
Value, as filed
$2.6M
157,307 sh × $16.41
Executed
Sep 8 2025
the trade date, as filed
Disclosed
Sep 8 2025
0 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
MMMichael A Metzger (Chief Executive Officer) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in Syndax Pharmaceuticals, Inc. (SNDX). The largest single filing was $785K of SNDX (32,375 sh × $24.24, as filed), executed Jul 8.
The name
SNDXHealthcare · Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Michael A Metzger in SNDX
SNDXSALE
Syndax Pharmaceuticals, Inc.
$785K32,375 sh × $24.24
Exec Jul 8
Filed Jul 9 · 4:54 PM ET SNDXSALE Syndax Pharmaceuticals, Inc. $130K
6,847 sh × $18.99
Exec Jun 1
Filed Jun 2 · 5:30 PM ET SNDXSALE Syndax Pharmaceuticals, Inc. $361K
17,159 sh × $21.03
Exec Feb 9
Filed Feb 10 · 5:30 PM ET SNDXSALE Syndax Pharmaceuticals, Inc. $153K
7,412 sh × $20.62
Exec Feb 6
Filed Feb 6 · 5:30 PM ET SNDXSALE Syndax Pharmaceuticals, Inc. $118K
7,814 sh × $15.05
Exec Mar 4 2025
Filed Mar 6 2025 · 5:30 PM ET SNDXSALE Syndax Pharmaceuticals, Inc. $206K
13,288 sh × $15.50
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET